What question did this study set out to answer?

The research aims to evaluate the safety and efficacy of seltorexant compared to quetiapine in treating major depressive disorder (MDD).

Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study

View Full Paper

Ask AI

Bookmark

The research aims to evaluate the safety and efficacy of seltorexant compared to quetiapine in treating major depressive disorder (MDD).
Randomized, flexible-dose, parallel-group design
Participants received either seltorexant 20 mg or quetiapine extended release
Duration of the study was 6 months
Focus on patients with MDD and insomnia symptoms
Seltorexant demonstrated favorable tolerability compared to quetiapine
Preliminary efficacy of seltorexant was noted in MDD patients
Indications of potential differentiation from quetiapine were observed

No takes yet. Share an insight, caveat, or question.

Exploratory study shows seltorexant improves symptoms in major depressive disorder, indicating a potential new treatment option.

Pinter et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark